Skip to main content
Glama

Compare Entities

compare_entities
Read-onlyIdempotent

"Compare X and Y" / "X vs Y" / "X versus Y" / "which is bigger / better / larger / more profitable" / "rank these companies" / "head to head" — side-by-side comparison of 2–5 companies or drugs in ONE parallel call. ALWAYS PREFER over sequential single-pack lookups when comparing entities. type="company" pulls LATEST 10-K revenue + net income + cash + long-term debt from SEC EDGAR/XBRL (off-calendar fiscal years handled correctly — AAPL Sep, NVDA Jan, etc.). type="drug" pulls FAERS adverse-event counts, FDA approval counts, active trial counts. Results sorted by primary metric so "largest" / "most" / "biggest" reads off the top of the response. Returns paired data + pipeworx:// citation URIs per entity. Replaces 8–15 sequential lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valuesYesFor company: 2–5 tickers/CIKs (e.g., ["AAPL","MSFT"]). For drug: 2–5 names (e.g., ["ozempic","mounjaro"]).

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. First observed

TDQS

A4.8/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations already declare read-only, idempotent, and non-destructive behavior, and the description adds substantial context: data sources (SEC EDGAR/XBRL, FAERS), specific metrics pulled (revenue, net income, cash, long-term debt, adverse-event counts), fiscal-year handling, sorting behavior, and citation URIs. This goes well beyond the annotations.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is longer than minimal, but every sentence contributes: query examples, data sources, metrics, sorting, count limits, and output format. It is front-loaded with purpose and not repetitive.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

Given no output schema, the description is thorough: it covers input constraints (2–5 entities), data sources, per-type behavior, sorting, output shape (paired data + citation URIs), and efficiency benefit. Context is complete for an agent to select and invoke appropriately.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters4/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema descriptions cover 100% of parameters, so the baseline is 3. The description adds value by providing concrete examples (AAPL/MSFT, ozempic/mounjaro) and clarifying that values can be tickers/CIKs for companies and drug names for drugs, making parameter semantics more intuitive.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description clearly states the tool's purpose: side-by-side comparison of 2–5 companies or drugs with explicit query examples. It distinguishes from siblings by emphasizing a single parallel call and contrasting with sequential single-pack lookups.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines5/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description provides explicit when-to-use instructions with query triggers and a preference directive: 'ALWAYS PREFER over sequential single-pack lookups when comparing entities.' This effectively guides selection versus alternative approaches.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

Try in Browser

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

B3.4/5.0
Disambiguation2/5

The set mixes several overlapping query surfaces: ask_pipeworx and ask_pipeworx_beta are currently identical, ask_pipeworx_grounded/deep_research/discover_tools/suggest_questions all serve related retrieval/discovery purposes, and the five polymarket_* tools have similar opportunity-finding goals. Only the unusually detailed descriptions save some tools from misselection; an agent would struggle to quickly pick the right one.

Naming Consistency4/5

Names are uniformly snake_case and mostly follow a verb_noun or prefixed_noun pattern (ask_pipeworx, validate_claim, polymarket_edges, scan_dependency). Minor inconsistencies exist — bare nouns like gene/variant/search sit alongside compound names like generate_llms_txt, and the pipeworx_ prefix isn't applied to ask_pipeworx/deep_research — but the overall style is recognizable and predictable.

Tool Count2/5

36 tools is too many for a coherent server, especially since the domains are largely unrelated: 5 gnomAD genomics tools, 20+ Pipeworx/Polymarket data tools, memory CRUD, subscription management, and a couple of web-dev utilities. The count doesn't align with a single obvious scope and would overwhelm an agent selecting among them.

Completeness3/5

Within the major subdomains coverage is strong: memory has remember/recall/forget, subscriptions have full lifecycle tools, and Polymarket has edge detection plus fill-risk checking. However, there are notable gaps — no tool to fetch a pipeworx:// citation URI despite deep_research promising resolvable citations, and the gnomAD surface lacks batch queries, coverage, or constraint data for a server named Gnomad.